Literature DB >> 31179825

GAN (gigaxonin) E3 ligase and ATG16L1: master and commander of autophagosome production.

Pascale Bomont1.   

Abstract

The sequential action of ATG proteins guarantees the formation of the autophagosome from the steps of the induction, nucleation, elongation and sealing of the phagophore membrane. Posttranslational modifications further add to the fine-tuning regulation of this highly ordered machinery and confer, in space and time, the dynamics necessary to respond to macroautophagy/autophagy activation, and to shut it down. Recently, we reported the discovery of GAN (gigaxonin), an E3 ubiquitin ligase adaptor as a key regulator of the elongation step of phagophore formation. GAN interacts, ubiquitinates and degrades ATG16L1, which forms a complex with the ATG12-ATG5 ubiquitin-like conjugation system, and specifies the site of lipidation of LC3 by this complex onto the nascent phagophore. Accordingly, depletion of GAN in primary neurons causes the accumulation of ATG16L1 and decreases the autophagy flux by impairing the net production of autophagosomes. Considering the pivotal role of ATG16L1 in autophagy, and the reversal of the deficits upon reintroduction of GAN, one can speculate that GAN constitutes a novel molecular switch to fine tune the autophagy machinery.

Entities:  

Keywords:  ATG16L1; E3 ligase; GAN/gigaxonin; autophagosome production; ubiquitin-mediated degradation

Mesh:

Substances:

Year:  2019        PMID: 31179825      PMCID: PMC6693447          DOI: 10.1080/15548627.2019.1628546

Source DB:  PubMed          Journal:  Autophagy        ISSN: 1554-8627            Impact factor:   16.016


  1 in total

1.  Gigaxonin E3 ligase governs ATG16L1 turnover to control autophagosome production.

Authors:  Aurora Scrivo; Patrice Codogno; Pascale Bomont
Journal:  Nat Commun       Date:  2019-02-15       Impact factor: 14.919

  1 in total
  1 in total

Review 1.  E3 Ubiquitin Ligases in Neurological Diseases: Focus on Gigaxonin and Autophagy.

Authors:  Léa Lescouzères; Pascale Bomont
Journal:  Front Physiol       Date:  2020-10-22       Impact factor: 4.566

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.